SK42899A3 - 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds - Google Patents

3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds Download PDF

Info

Publication number
SK42899A3
SK42899A3 SK428-99A SK42899A SK42899A3 SK 42899 A3 SK42899 A3 SK 42899A3 SK 42899 A SK42899 A SK 42899A SK 42899 A3 SK42899 A3 SK 42899A3
Authority
SK
Slovakia
Prior art keywords
substituted
alkoxyisoxazol
alkyl
acid derivatives
hydrogen
Prior art date
Application number
SK428-99A
Other languages
English (en)
Slovak (sk)
Inventor
Benny Bang-Andersen
Klaus P Bogeso
Povl Krogsgaard-Larsen
Lenz S Moltzen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SK42899A3 publication Critical patent/SK42899A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SK428-99A 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds SK42899A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK109296 1996-10-04
PCT/DK1997/000426 WO1998015542A1 (en) 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Publications (1)

Publication Number Publication Date
SK42899A3 true SK42899A3 (en) 1999-08-06

Family

ID=8100908

Family Applications (1)

Application Number Title Priority Date Filing Date
SK428-99A SK42899A3 (en) 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Country Status (26)

Country Link
US (1) US6200999B1 (uk)
EP (1) EP0934286B1 (uk)
JP (1) JP2001501630A (uk)
KR (1) KR20000048908A (uk)
CN (1) CN1238766A (uk)
AR (1) AR008880A1 (uk)
AT (1) ATE230734T1 (uk)
AU (1) AU733004B2 (uk)
BG (1) BG103348A (uk)
BR (1) BR9712198A (uk)
CA (1) CA2268028C (uk)
CZ (1) CZ116899A3 (uk)
DE (1) DE69718338T2 (uk)
EA (1) EA001625B1 (uk)
ES (1) ES2189978T3 (uk)
HU (1) HUP0000084A3 (uk)
IL (1) IL129135A0 (uk)
IS (1) IS5009A (uk)
NO (1) NO312961B1 (uk)
NZ (1) NZ334798A (uk)
PL (1) PL332553A1 (uk)
SK (1) SK42899A3 (uk)
TR (1) TR199900724T2 (uk)
UA (1) UA52698C2 (uk)
WO (1) WO1998015542A1 (uk)
ZA (1) ZA978877B (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
JP4052573B2 (ja) 2000-09-15 2008-02-27 バーテックス ファーマシューティカルズ インコーポレイテッド イソオキサゾールおよびｅｒｋのインヒビターとしてのその使用
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
PL1611144T3 (pl) 2003-04-09 2011-03-31 Wyeth Llc Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
AU2006301376A1 (en) * 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
GB2470495B (en) * 2008-01-16 2012-12-26 Biotechnology Res Corp Ltd Oxazolidine derivatives as NMDA antagonists
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
US10442768B2 (en) 2016-01-21 2019-10-15 Agro-Kanesho Co., Ltd. Method for producing 2-aminonicotinic acid benzyl ester derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0456519T3 (da) 1990-05-11 1994-11-07 Sankyo Co Piperidyloxy- og quinuclidinyloxyisoxazolderivater, deres fremstilling og deres terapeutiske anvendelse
AU678186B2 (en) 1992-10-23 1997-05-22 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds

Also Published As

Publication number Publication date
WO1998015542A1 (en) 1998-04-16
HUP0000084A2 (hu) 2000-06-28
ES2189978T3 (es) 2003-07-16
CA2268028A1 (en) 1998-04-16
TR199900724T2 (xx) 1999-06-21
US6200999B1 (en) 2001-03-13
AR008880A1 (es) 2000-02-23
CA2268028C (en) 2003-03-18
NZ334798A (en) 2000-06-23
BR9712198A (pt) 1999-08-31
JP2001501630A (ja) 2001-02-06
EP0934286B1 (en) 2003-01-08
DE69718338T2 (de) 2003-10-16
IL129135A0 (en) 2000-02-17
AU733004B2 (en) 2001-05-03
EA001625B1 (ru) 2001-06-25
EA199900358A1 (ru) 1999-10-28
HUP0000084A3 (en) 2001-12-28
CN1238766A (zh) 1999-12-15
IS5009A (is) 1999-03-23
EP0934286A1 (en) 1999-08-11
NO991561L (no) 1999-06-04
AU4451797A (en) 1998-05-05
PL332553A1 (en) 1999-09-13
ATE230734T1 (de) 2003-01-15
DE69718338D1 (de) 2003-02-13
BG103348A (en) 1999-11-30
KR20000048908A (ko) 2000-07-25
NO312961B1 (no) 2002-07-22
NO991561D0 (no) 1999-03-30
ZA978877B (en) 1998-04-17
UA52698C2 (uk) 2003-01-15
CZ116899A3 (cs) 1999-09-15

Similar Documents

Publication Publication Date Title
JP4430941B2 (ja) Ｅｄｇ受容体作動薬
JPH11509175A (ja) Ｎ−ヘテロアリールピリジンスルホンアミド誘導体およびエンドテリンアンタゴニストとしてのそれらの使用
USRE38200E1 (en) Indole-2,3-dione-3-oxime derivatives
KR20210024574A (ko) 세포 괴사 억제제 및 이의 제조 방법과 용도
JPWO2007129745A1 (ja) ヘテロアリールアミド低級カルボン酸誘導体
SK42899A3 (en) 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds
JPH04234857A (ja) ３，５−ジ置換２−イソキサゾリンおよびイソキサゾール、それらの製法およびそれらを含有する薬学的組成物
AU2001264116B2 (en) Amidine derivatives as selective antagonists of NMDA receptors
US10117864B2 (en) Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
EP1167369A1 (en) Novel thiazolobenzimidazole derivatives
JP2009523711A (ja) 新規環状置換フロピリミジン誘導体および心臓血管疾患を処置するためのその使用
US6239128B1 (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
RU2138488C1 (ru) Соединения 2-аминокарбоновой кислоты, замещенной 5-арилизоксазол-4-илом, и фармацевтическая композиция на их основе
JP2650739B2 (ja) 分割化アミノピロリジン神経防護剤
US11149018B2 (en) Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
US11136296B2 (en) Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
WO2017153231A1 (de) Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung